

NASPCC Symposium on Immuno-Oncology in Prostate Cancer: Current and Future Trends

June 24, 2021

10:00 am – 2:30 pm (Pacific)

1:00 pm – 5:30 pm (Eastern)

10:00 am – 10:05 am Introduction
Merel Nissenberg, Esq., President, NASPCC

10:05 am – 10:15 am Introductory Remarks
Saul Priceman, PhD
City of Hope Medical Center

Session One

10:15 am – 10:35 am Redirecting T-Cells for Prostate Cancer Immunotherapy
Lawrence Fong, MD
University of California, San Francisco


10:40 am – 11:00 am CAR-T Development in Sub-Types of Prostate Cancer: How
Mechanistic Biology Impacts Future Therapies
John Lee, MD, PhD
Fred Hutchinson Cancer Center

11:05 am – 11:25 am Chimeric Antigen Receptor T-Cell Therapies for Advanced
Prostate Cancer: Clinical Trials (and Tribulations)
Vivek Narayen, MD, MS
University of Pennsylvania

11:30 am – 11:50 am Advancing CAR-T Cells for Prostate Cancer
Saul Priceman, PhD
City of Hope Medical Center

11:50 am – 12:10 pm **Panel Discussion**

12:10 pm – 12:25 pm **Break**



Session Two

- 12:30 pm – 12:50 pm Upcoming Clinical Trial of AMG 757, a DLL3/CD3 BiTE, in Neuroendocrine Prostate Cancer
Rahul Aggarwal, MD
University of California, San Francisco
- 12:55 pm – 1:15 pm Anti-CTLA-4-Therapy in Prostate Cancer
Sumit Subudhi, MD, PhD
UT MD Anderson Cancer Center
- 1:20 pm – 1:40 pm The QuEST for an Effective Immunotherapy for Prostate Cancer
James Gulley, MD, PhD
National Institutes of Health (NIH)
- 1:45 pm – 2:05 pm Allogenic Approaches to Cell Therapy for Tumors of Various Sorts
Charles Drake, MD, PhD
New York-Presbyterian/Columbia
- 2:10 pm – 2:30 pm **Panel Discussion**
- 2:30 pm **Closing Remarks**